Search

Your search keyword '"Bortolotti R"' showing total 117 results
Start Over Author "Bortolotti R"
117 results on '"Bortolotti R"'

2. AB0771 FEMALE GENDER AND STEROID TREATMENT AS MAIN INFLUENCING FACTORS IN THE PERCEPTION OF QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS: FINAL RESULTS FROM THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE

Author

Treppo, E., primary, Isola, M., additional, De Martino, M., additional, Padoan, R., additional, Urban, M. L., additional, Monti, S., additional, Sartorelli, S., additional, Giollo, A., additional, Argolini, L. M., additional, Marvisi, C., additional, Gattamelata, A., additional, Regola, F., additional, Ferro, F., additional, Cassone, G., additional, Motta, F., additional, Berti, A., additional, Conticini, E., additional, Guiducci, S., additional, Matucci-Cerinic, M., additional, Lo Gullo, A., additional, Manfredi, A., additional, Frediani, B., additional, Bortolotti, R., additional, Selmi, C., additional, Baldini, C., additional, Franceschini, F., additional, Conti, F., additional, Emmi, G., additional, Caporali, R., additional, Rossini, M., additional, Dagna, L., additional, Montecucco, C., additional, Schiavon, F., additional, Salvarani, C., additional, De Vita, S., additional, and Quartuccio, L., additional

Published
2023
Full Text
View/download PDF

4. POS1176 HOSPITALIZATION RATES, FEATURES, AND DISCHARGE DIAGNOSES OF A LARGE NATIONWIDE COHORT OF ANCA-ASSOCIATED VASCULITIS

Author

Berti, A., primary, Ottone, M., additional, Sartorelli, S., additional, Treppo, E., additional, Bettiol, A., additional, Padoan, R., additional, Regola, F., additional, Monti, S., additional, Marvisi, C., additional, Giollo, A., additional, Argolini, L. M., additional, Righini, M., additional, Gattamelata, A., additional, Cassone, G., additional, Sottini, L., additional, Maule, M., additional, Toniati, P., additional, Palermo, B. L., additional, Bello, F., additional, Guella, S., additional, Izzo, R., additional, Muratore, F., additional, Catanoso, M. G., additional, Fassio, A., additional, Cataleta, P., additional, Buscaroli, A., additional, Giorgi Rossi, P., additional, Franceschini, F., additional, Caporali, R., additional, Montecucco, C., additional, Conti, F., additional, Emmi, G., additional, Quartuccio, L., additional, Paolazzi, G., additional, Dagna, L., additional, Schiavon, F., additional, Salvarani, C., additional, and Bortolotti, R., additional

Published
2023
Full Text
View/download PDF

6. AB1462 RHEUMATIC IMMUNE- AND NONIMMUNE-RELATED ADVERSE EVENTS IN PHASE 3 CLINICAL TRIALS ASSESSING PD-(L)1 CHECKPOINT INHIBITORS FOR LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

Author

Veccia, A., primary, Kostine, M., additional, Tison, A., additional, Dipasquale, M., additional, Kingspergher, S., additional, Grandi, G., additional, Caffo, O., additional, Inchiostro, S., additional, Paolazzi, G., additional, Bortolotti, R., additional, Cornec, D., additional, and Berti, A., additional

Published
2022
Full Text
View/download PDF

8. AB0627 Evaluation of internal consistency, feasibility, and reliability of the Italian version of ANCA-associated vasculitis patient-reported outcome (AAV-PRO_ita) questionnaire: preliminary results from a multicenter study on a large cohort of Italian patients

Author

Treppo, E., primary, Isola, M., additional, De Martino, M., additional, Padoan, R., additional, Urban, M. L., additional, Monti, S., additional, Sartorelli, S., additional, Giollo, A., additional, Argolini, L. M., additional, Marvisi, C., additional, Ferro, F., additional, Cassone, G., additional, Motta, F., additional, Berti, A., additional, Conticini, E., additional, Manfredi, A., additional, Frediani, B., additional, Bortolotti, R., additional, Selmi, C., additional, Baldini, C., additional, Emmi, G., additional, Caporali, R., additional, Rossini, M., additional, Dagna, L., additional, Montecucco, C., additional, Schiavon, F., additional, Salvarani, C., additional, De Vita, S., additional, and Quartuccio, L., additional

Published
2022
Full Text
View/download PDF

9. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Author

Bettiol, A., Urban, M. L., Dagna, L., Cottin, V., Franceschini, F., Del Giacco, S., Schiavon, F., Neumann, T., Lopalco, G., Novikov, P., Baldini, C., Lombardi, C., Berti, A., Alberici, F., Folci, M., Negrini, S., Sinico, R. A., Quartuccio, L., Lunardi, C., Parronchi, P., Moosig, F., Espigol-Frigole, G., Schroeder, J., Kernder, A. L., Monti, S., Silvagni, E., Crimi, C., Cinetto, F., Fraticelli, P., Roccatello, D., Vacca, A., Mohammad, A. J., Hellmich, B., Samson, M., Bargagli, E., Cohen Tervaert, J. W., Ribi, C., Fiori, D., Bello, F., Fagni, F., Moroni, L., Ramirez, G. A., Nasser, M., Marvisi, C., Toniati, P., Firinu, D., Padoan, R., Egan, A., Seeliger, B., Iannone, F., Salvarani, C., Jayne, D., Prisco, D., Vaglio, A., Emmi, G., Ahmad, K., Beccalli, M., Bonnotte, B., Bortolotti, R., Cariddi, A., Caminati, M., Cid, M. C., Deidda, M., Delvino, P., Scala, G. D., Felicetti, M., Ferro, F., Furini, F., Gelain, E., Ghirelli, G., Holle, J., Losappio, L. M., Mahr, A., Malandrino, D., Marhhold, J., Mattioli, I., Moi, L., Moiseev, S., Muratore, F., Nolasco, S., Olivieri, B., Palermo, A., Regola, F., Sander, O., Scarpa, R., Sciascia, S., Silvestri, E., Susca, N., Terrier, B., Treppo, E., Trezzi, B., Uzzo, M., Vitiello, G., Yacyshyn, E., RS: MHeNs - R3 - Neuroscience, Faculteit FHML Centraal, Bettiol, A, Urban, M, Dagna, L, Cottin, V, Franceschini, F, Del Giacco, S, Schiavon, F, Neumann, T, Lopalco, G, Novikov, P, Baldini, C, Lombardi, C, Berti, A, Alberici, F, Folci, M, Negrini, S, Sinico, R, Quartuccio, L, Lunardi, C, Parronchi, P, Moosig, F, Espígol-Frigolé, G, Schroeder, J, Kernder, A, Monti, S, Silvagni, E, Crimi, C, Cinetto, F, Fraticelli, P, Roccatello, D, Vacca, A, Mohammad, A, Hellmich, B, Samson, M, Bargagli, E, Cohen Tervaert, J, Ribi, C, Fiori, D, Bello, F, Fagni, F, Moroni, L, Ramirez, G, Nasser, M, Marvisi, C, Toniati, P, Firinu, D, Padoan, R, Egan, A, Seeliger, B, Iannone, F, Salvarani, C, Jayne, D, Prisco, D, Vaglio, A, Emmi, G, Jayne, David [0000-0002-1712-0637], and Apollo - University of Cambridge Repository

Subjects
Male, Epidemiology, Birmingham Vasculitis Activity Score, law.invention, Glucocorticoid, Randomized controlled trial, Prednisone, law, Eosinophilic, Monoclonal, Immunology and Allergy, Humanized, PLACEBO, Middle Aged, egpa mepolizumab, Treatment Outcome, SAFETY, Female, ANCA-associated Vasculitis, Biologicals, Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss), Glucocorticoids, Granulomatosis with polyangiitis, ANCA-associated Vasculiti, medicine.drug, Keywords: ANCA-associated Vasculitis, Adult, medicine.medical_specialty, Immunology, Antibodies, Monoclonal, Humanized, Antibodies, Drug Administration Schedule, Eosinophilia, Granulomatosis with Polyangiitis, Humans, Retrospective Studies, Rheumatology, Internal medicine, medicine, Adverse effect, Asthma, business.industry, medicine.disease, Biological, EGPA, European EGPA Study Group, business, FOLLOW-UP, Mepolizumab
Abstract

OBJECTIVE: Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In a few recently reported studies, successful real-life experiences with the approved dose for treating severe eosinophilic asthma (100 mg every 4 weeks) were observed. We undertook this study to assess the effectiveness and safety of mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks in a large European EGPA cohort. METHODS: We included all patients with EGPA treated with mepolizumab at the recruiting centers in 2015-2020. Treatment response was evaluated from 3 months to 24 months after initiation of mepolizumab. Complete response to treatment was defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] = 0) and a prednisolone or prednisone dose (or equivalent) of ���4 mg/day. Respiratory outcomes included asthma and ear, nose, and throat (ENT) exacerbations. RESULTS: Two hundred three patients, of whom 191 received a stable dose of mepolizumab (158 received 100 mg every 4 weeks and 33 received 300 mg every 4 weeks) were included. Twenty-five patients (12.3%) had a complete response to treatment at 3 months. Complete response rates increased to 30.4% and 35.7% at 12 months and 24 months, respectively, and rates were comparable between mepolizumab 100 mg every 4 weeks and 300 mg every 4 weeks. Mepolizumab led to a significant reduction in BVAS score, prednisone dose, and eosinophil counts from 3 months to 24 months, with no significant differences observed between 100 mg every 4 weeks and 300 mg every 4 weeks. Eighty-two patients (40.4%) experienced asthma exacerbations (57 of 158 [36%] who received 100 mg every 4 weeks; 17 of 33 [52%] who received 300 mg every 4 weeks), and 31 patients (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events (AEs), most of which were nonserious AEs (38 of 44). CONCLUSION: Mepolizumab at both 100 mg every 4 weeks and 300 mg every 4 weeks is effective for the treatment of EGPA. The 2 doses should be compared in the setting of a controlled trial.

Published
2022
Full Text
View/download PDF

10. EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS

Author

Treppo, E, Isola, M, De Martino, M, Padoan, R, Urban, Ml, Monti, S, Sartorelli, S, Giollo, A, Argolini, Lm, Marvisi, C, Ferro, F, Cassone, G, Motta, F, Berti, A, Conticini, E, Manfredi, A, Frediani, B, Bortolotti, R, Selmi, C, Baldini, C, Emmi, G, Caporali, R, Rossini, M, Dagna, L, Montecucco, C, Schiavon, F, Salvarani, C, De Vita, S, and Quartuccio, L

Published
2022

11. Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

Author

Bettiol, A., Sinico, R. A., Schiavon, F., Monti, S., Bozzolo, E. P., Franceschini, F., Govoni, M., Lunardi, C., Guida, G., Lopalco, G., Paolazzi, G., Vacca, A., Gregorini, G., Leccese, P., Piga, M., Conti, F., Fraticelli, P., Quartuccio, L., Alberici, F., Salvarani, C., Bettio, S., Negrini, S., Selmi, C., Sciascia, S., Moroni, G., Colla, L., Manno, C., Urban, M. L., Vannacci, A., Pozzi, M. R., Fabbrini, P., Polti, S., Felicetti, M., Marchi, M. R., Padoan, R., Delvino, P., Caporali, R., Montecucco, C., Dagna, L., Cariddi, A., Toniati, P., Tamanini, S., Furini, F., Bortoluzzi, A., Tinazzi, E., Delfino, L., Badiu, I., Rolla, G., Venerito, V., Iannone, F., Berti, A., Bortolotti, R., Racanelli, V., Jeannin, G., Padula, A., Cauli, A., Priori, R., Gabrielli, A., Bond, M., Tedesco, M., Pazzola, G., Tomietto, P., Pellecchio, M., Marvisi, C., Maritati, F., Palmisano, A., Dejaco, C., Willeit, J., Kiechl, S., Olivotto, I., Willeit, P., Prisco, D., Vaglio, A., Emmi, G., Bargagli, E., Becatti, M., Beccalli, M., Bello, F., Bozzao, F., Canti, V., Cassia, M. A., Cassone, G., Catanoso, M., Chieco-Bianchi, F., Clari, R., Coladonato, L., De Santis, M., Di Scala, G., Fagni, F., Fenaroli, P., Fiorillo, C., Floris, A., Fornaro, M., Galli, E., Generali, E., Giliberti, M., Lascaro, N., Leccese, I., Mattioli, I., Olivieri, B., Osti, N., Peyronel, F., Radin, M., Righetti, G., Salvati, S., Silvestri, E., Susca, N., Tamburini, C., Taurisano, G., Trezzi, B., Trivioli, G., Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, and Emmi, G

Subjects
Pulmonary and Respiratory Medicine, Burden of disease, Humans, Churg-Strauss Syndrome, Granulomatosis with Polyangiitis, Venous Thromboembolism, Venous Thrombosis, Churg-strauss syndrome, Criminology, NO, 03 medical and health sciences, 0302 clinical medicine, Medicine, 030212 general & internal medicine, Vascular inflammation, business.industry, Conflict of interest, Cytoplasmic antibody, medicine.disease, 030228 respiratory system, Wegener granulomatosis, arterial and venous thromboembolic events, Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome), Organ involvement, business, Production team
Abstract

Eosinophilic Granulomatosis with Polyangiitis (EGPA, Churg-Strauss syndrome) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) characterised by respiratory manifestations and systemic organ involvement [1]. Particularly, cardiac manifestations occur in 40–60% of patients, representing the leading cause of mortality [2]. Recent reports suggest that venous thromboembolic events might also represent a consistent burden of disease [3, 4], as already known for the other AAVs [5–7], possibly due to eosinophil-mediated vascular inflammation [5]. Nevertheless, the occurrence of arterial and venous thrombotic events (AVTE) has never been systematically explored in EGPA. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Alessandra Bettiol Conflict of interest: Renato Alberto Sinico Conflict of interest: Franco Schiavon Conflict of interest: Sara Monti Conflict of interest: Enrica Paola Bozzolo Conflict of interest: Franco Franceschini Conflict of interest: Marcello Govoni Conflict of interest: Claudio Lunardi Conflict of interest: Giuseppe Guida Conflict of interest: Giuseppe Lopalco Conflict of interest: Giuseppe Paolazzi Conflict of interest: Angelo Vacca Conflict of interest: Gina Gregorini Conflict of interest: Pietro Leccese Conflict of interest: Matteo Piga Conflict of interest: Fabrizio Conti Conflict of interest: Paolo Fraticelli Conflict of interest: Luca Quartuccio Conflict of interest: Federico Alberici Conflict of interest: Carlo Salvarani Conflict of interest: Silvano Bettio Conflict of interest: Simone Negrini Conflict of interest: Carlo Selmi Conflict of interest: Savino Sciascia Conflict of interest: Gabriella Moroni Conflict of interest: Loredana Colla Conflict of interest: Carlo Manno Conflict of interest: Maria Letizia Urban Conflict of interest: Alfredo Vannacci Conflict of interest: Maria Rosa Pozzi Conflict of interest: Paolo Fabbrini Conflict of interest: Stefano Polti Conflict of interest: Mara Felicetti Conflict of interest: Maria Rita Marchi Conflict of interest: Roberto Padoan Conflict of interest: Paolo Delvino Conflict of interest: Roberto Caporali Conflict of interest: Carlomaurizio Montecucco Conflict of interest: Lorenzo Dagna Conflict of interest: Adriana Cariddi Conflict of interest: Paola Toniati Conflict of interest: Dr. Tamanini reports other from Glaxo Smith Kline, outside the submitted work. Conflict of interest: Federica Furini Conflict of interest: Alessandra Bortoluzzi Conflict of interest: Elisa Tinazzi Conflict of interest: Lorenzo Delfino Conflict of interest: Iuliana Badiu Conflict of interest: Giovanni Rolla Conflict of interest: Vincenzo Venerito Conflict of interest: Florenzo Iannone Conflict of interest: Alvise Berti Conflict of interest: Roberto Bortolotti Conflict of interest: Vito Racanelli Conflict of interest: Guido Jeannin Conflict of interest: Angela Padula Conflict of interest: Alberto Cauli Conflict of interest: Roberta Priori Conflict of interest: Armando Gabrielli Conflict of interest: Milena Bond Conflict of interest: Martina Tedesco Conflict of interest: Giulia Pazzola Conflict of interest: Paola Tomietto Conflict of interest: Marco Pellecchio Conflict of interest: Chiara Marvisi Conflict of interest: Federica Maritati Conflict of interest: Alessandra Palmisano Conflict of interest: Christian Dejaco Conflict of interest: Johann Willeit Conflict of interest: Stefan Kiechl Conflict of interest: Iacopo Olivotto Conflict of interest: Peter Willeit Conflict of interest: Domenico Prisco Conflict of interest: Augusto Vaglio Conflict of interest: Giacomo Emmi

Published
2020

12. Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)

Author

Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Sinico, Renato Alberto, Schiavon, Franco, Monti, Sara, Bozzolo, Enrica Paola, Franceschini, Franco, Govoni, Marcello, Lunardi, Claudio, Guida, Giuseppe, Lopalco, Giuseppe, Paolazzi, Giuseppe, Vacca, Angelo, Gregorini, Gina, Leccese, Pietro, Piga, Matteo, Conti, Fabrizio, Fraticelli, Paolo, Quartuccio, Luca, Alberici, Federico, Salvarani, Carlo, Bettio, Silvano, Negrini, Simone, Selmi, Carlo, Sciascia, Savino, Moroni, Gabriella, Colla, Loredana, Manno, Carlo, Urban, Maria Letizia, Vannacci, Alfredo, Pozzi, Maria Rosa, Fabbrini, Paolo, Polti, Stefano, Felicetti, Mara, Marchi, Maria Rita, Padoan, Roberto, Delvino, Paolo, Caporali, Roberto, Montecucco, Carlomaurizio, Dagna, Lorenzo, Cariddi, Adriana, Toniati, Paola, Tamanini, Silvia, Furini, Federica, Bortoluzzi, Alessandra, Tinazzi, Elisa, Delfino, Lorenzo, Badiu, Iuliana, Rolla, Giovanni, Venerito, Vincenzo, Iannone, Florenzo, Berti, Alvise, Bortolotti, Roberto, Racanelli, Vito, Jeannin, Guido, Padula, Angela, Cauli, Alberto, Priori, Roberta, Gabrielli, Armando, Bond, Milena, Tedesco, Martina, Pazzola, Giulia, Tomietto, Paola, Pellecchio, Marco, Marvisi, Chiara, Maritati, Federica, Palmisano, Alessandra, Dejaco, Christian, Willeit, Johann, Kiechl, Stefan, Olivotto, Iacopo, Willeit, Peter, Prisco, Domenico, Vaglio, Augusto, Emmi, Giacomo, Bettiol, A, Sinico, R, Schiavon, F, Monti, S, Bozzolo, E, Franceschini, F, Govoni, M, Lunardi, C, Guida, G, Lopalco, G, Paolazzi, G, Vacca, A, Gregorini, G, Leccese, P, Piga, M, Conti, F, Fraticelli, P, Quartuccio, L, Alberici, F, Salvarani, C, Bettio, S, Negrini, S, Selmi, C, Sciascia, S, Moroni, G, Colla, L, Manno, C, Urban, M, Vannacci, A, Pozzi, M, Fabbrini, P, Polti, S, Felicetti, M, Marchi, M, Padoan, R, Delvino, P, Caporali, R, Montecucco, C, Dagna, L, Cariddi, A, Toniati, P, Tamanini, S, Furini, F, Bortoluzzi, A, Tinazzi, E, Delfino, L, Badiu, I, Rolla, G, Venerito, V, Iannone, F, Berti, A, Bortolotti, R, Racanelli, V, Jeannin, G, Padula, A, Cauli, A, Priori, R, Gabrielli, A, Bond, M, Tedesco, M, Pazzola, G, Tomietto, P, Pellecchio, M, Marvisi, C, Maritati, F, Palmisano, A, Dejaco, C, Willeit, J, Kiechl, S, Olivotto, I, Willeit, P, Prisco, D, Vaglio, A, Emmi, G, Bettiol, Alessandra, Sinico, Renato Alberto, Schiavon, Franco, Monti, Sara, Bozzolo, Enrica Paola, Franceschini, Franco, Govoni, Marcello, Lunardi, Claudio, Guida, Giuseppe, Lopalco, Giuseppe, Paolazzi, Giuseppe, Vacca, Angelo, Gregorini, Gina, Leccese, Pietro, Piga, Matteo, Conti, Fabrizio, Fraticelli, Paolo, Quartuccio, Luca, Alberici, Federico, Salvarani, Carlo, Bettio, Silvano, Negrini, Simone, Selmi, Carlo, Sciascia, Savino, Moroni, Gabriella, Colla, Loredana, Manno, Carlo, Urban, Maria Letizia, Vannacci, Alfredo, Pozzi, Maria Rosa, Fabbrini, Paolo, Polti, Stefano, Felicetti, Mara, Marchi, Maria Rita, Padoan, Roberto, Delvino, Paolo, Caporali, Roberto, Montecucco, Carlomaurizio, Dagna, Lorenzo, Cariddi, Adriana, Toniati, Paola, Tamanini, Silvia, Furini, Federica, Bortoluzzi, Alessandra, Tinazzi, Elisa, Delfino, Lorenzo, Badiu, Iuliana, Rolla, Giovanni, Venerito, Vincenzo, Iannone, Florenzo, Berti, Alvise, Bortolotti, Roberto, Racanelli, Vito, Jeannin, Guido, Padula, Angela, Cauli, Alberto, Priori, Roberta, Gabrielli, Armando, Bond, Milena, Tedesco, Martina, Pazzola, Giulia, Tomietto, Paola, Pellecchio, Marco, Marvisi, Chiara, Maritati, Federica, Palmisano, Alessandra, Dejaco, Christian, Willeit, Johann, Kiechl, Stefan, Olivotto, Iacopo, Willeit, Peter, Prisco, Domenico, Vaglio, Augusto, and Emmi, Giacomo

Published
2021

13. D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study

Author

Palareti G., Legnani C., Antonucci E., Cosmi B., Poli D., Testa S., Tosetto A., Ageno W., Falanga A., Ferrini P. M., Pengo V., Prandoni P., Prisco D., Ghirarduzzi A., Veropalumbo M. R., Ugolotti M. C., Erba N., De Micheli V., Paoletti O., Luigi S., Donadini M., Rancan E., Quintavalla R., Santoro R. C., Orlandini F., Benedetti R., Cattaneo M., Lussana F., Bertinato E., Cappelli R., Pizzini A. M., D'Angelo A., Crippa L., Angeloni L., Bortolotti R., Vandelli M. R., Tripodi A., Imberti D., Moia M., Pesavento R., Magrini N., Marongiu F., Zonzin P., Piaggesi N., Silingardi M., Palareti G., Legnani C., Antonucci E., Cosmi B., Poli D., Testa S., Tosetto A., Ageno W., Falanga A., Ferrini P.M., Pengo V., Prandoni P., Prisco D., Ghirarduzzi A., Veropalumbo M.R., Ugolotti M.C., Erba N., De Micheli V., Paoletti O., Luigi S., Donadini M., Rancan E., Quintavalla R., Santoro R.C., Orlandini F., Benedetti R., Cattaneo M., Lussana F., Bertinato E., Cappelli R., Pizzini A.M., D'Angelo A., Crippa L., Angeloni L., Bortolotti R., Vandelli M.R., Tripodi A., Imberti D., Moia M., Pesavento R., Magrini N., Marongiu F., Zonzin P., Piaggesi N., Silingardi M., Palareti, G, Legnani, C, Antonucci, E, Cosmi, B, Poli, D, Testa, S, Tosetto, A, Ageno, W, Falanga, A, Ferrini, P, Pengo, V, and Prandoni, P

Subjects
Male, medicine.medical_specialty, Patients, medicine.drug_class, Cardiology, 030204 cardiovascular system & hematology, Individual risk, Cohort Studies, Fibrin Fibrinogen Degradation Products, 03 medical and health sciences, 0302 clinical medicine, Sex Factors, Predictive Value of Tests, Recurrence, Risk Factors, Internal medicine, Post-hoc analysis, D-dimer, Internal Medicine, medicine, Cutoff, Humans, 030212 general & internal medicine, Prospective Studies, Aged, business.industry, Gender, Anticoagulants, Venous Thromboembolism, Vitamin K antagonist, Middle Aged, Confidence interval, Telemedicine, Venous thromboembolism, Discontinuation, Im - Original, Emergency Medicine, Female, business
Abstract

Male patients, especially the young, are at a higher risk of recurrent venous thromboembolism (RVTE) than females. Recent scientific reports show the use of D-dimer does not help predict RVTE risk in males. In the present report, we reviewed the data obtained in the DULCIS study (main report published in Blood 2014), focusing on D-dimer results recorded in non-elderly patients of both genders included in the study, and their relationship with RVTE events occurring during follow-up. Using specifically designed cutoff values for positive/negative interpretation, serial D-dimer measurements (performed during warfarin treatment and up to 3 months after discontinuation of anticoagulation) in 475 patients (males 57.3%) aged ≤ 65 years were obtained. D-dimer resulted positive in 46.3% and 30.5% of males and females, respectively (p = 0.001). Following management procedure, anticoagulation was stopped in 53.7% of males and 69.5% of females, who had persistently negative D-dimer results. The rate of subsequent recurrent events was 1.7% (95% CI 0.5–4.5%) and 0.4% (95% CI 0–2.5%) patient-years in males and females, respectively, with upper limits of confidence intervals always below the level of risk considered acceptable by international scientific societies for stopping anticoagulation (

Published
2019

14. OP0093 RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLER’S SYNDROME

Author

Crisafulli, F., primary, Vitale, A., additional, Gaggiano, C., additional, Dagna, L., additional, Cavalli, G., additional, Cimaz, R., additional, Viapiana, O., additional, Iannone, F., additional, Lopalco, G., additional, Bortolotti, R., additional, Abdel Jaber, M., additional, Montecucco, C., additional, Monti, S., additional, Balduzzi, S., additional, Emmi, G., additional, Airò, P., additional, Franceschini, F., additional, Cantarini, L., additional, and Frassi, M., additional

Published
2021
Full Text
View/download PDF

15. FRI0212 THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS

Author

Monti, S., primary, Dagna, L., additional, Campochiaro, C., additional, Tomelleri, A., additional, Zanframundo, G., additional, Klersy, C., additional, Muratore, F., additional, Boiardi, L., additional, Padoan, R., additional, Felicetti, M., additional, Schiavon, F., additional, Bond, M., additional, Berti, A., additional, Bortolotti, R., additional, Nannini, C., additional, Cantini, F., additional, Giollo, A., additional, Conticini, E., additional, Gattamelata, A., additional, Priori, R., additional, Quartuccio, L., additional, Treppo, E., additional, Emmi, G., additional, Finocchi, M., additional, Cassone, G., additional, Hoxha, A., additional, Foti, R., additional, Colaci, M., additional, Caporali, R., additional, Salvarani, C., additional, and Montecucco, C., additional

Published
2020
Full Text
View/download PDF

16. OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS

Author

Ariani, A., primary, Bravi, E., additional, De Santis, M., additional, Hax, V., additional, Parisi, S., additional, Lumetti, F., additional, Girelli, F., additional, Saracco, M., additional, De Gennaro, F., additional, Giollo, A., additional, Abdel Jaber, M., additional, Bozzao, F., additional, Silva, M., additional, Ditto, M. C., additional, Lomater, C., additional, Mozzani, F., additional, Santilli, D., additional, Di Donato, E., additional, Becciolini, A., additional, Pucciarini, F., additional, Canziani, L., additional, Bodini, F. C., additional, Arrigoni, E., additional, Bredemeier, M., additional, Mendonça Da Silva Chakr, R., additional, Spinella, A., additional, Idolazzi, L., additional, Bortolotti, R., additional, Tomietto, P., additional, Baratella, E., additional, Tollot, S., additional, Giuggioli, D., additional, Fischetti, F., additional, Fusaro, E., additional, Sverzellati, N., additional, and Scirè, C. A., additional

Published
2020
Full Text
View/download PDF

17. FRI0350 FACTORS ASSOCIATED WITH PERIPHERAL EROSIVE RADIOGRAPHIC DISEASE IN A CONSECUTIVE SERIES OF 794 PSA PATIENTS

Author

Catanoso, M. G., primary, Macchioni, P., additional, Marchesoni, A., additional, D’angelo, S., additional, Ramonda, R., additional, Cauli, A., additional, Perrotta, F., additional, Bortolotti, R., additional, Lofrano, M., additional, Rotunno, L., additional, Lorenzin, M. G., additional, Valesini, G., additional, Mathieu, G., additional, Paolazzi, G., additional, and Salvarani, C., additional

Published
2020
Full Text
View/download PDF

18. Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group

Author

Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Sifuentes Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Pina Murcia, T, La Corte, R, Furini, F, Foschi, V, Bachiller Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bogliolo, L, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Salaffi, F, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Sifuentes Giraldo W. A., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Pina Murcia T., La Corte R., Furini F., Foschi V., Bachiller Corral J., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bogliolo L., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Salaffi F., Montecucco C., Gonzalez-Gay M. A., Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Sifuentes Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Pina Murcia, T, La Corte, R, Furini, F, Foschi, V, Bachiller Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bogliolo, L, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Salaffi, F, Montecucco, C, Gonzalez-Gay, M, Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Sifuentes Giraldo W. A., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Pina Murcia T., La Corte R., Furini F., Foschi V., Bachiller Corral J., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bogliolo L., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Salaffi F., Montecucco C., and Gonzalez-Gay M. A.

Abstract

Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD), an autoimmune disease characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). Recently, we organized an international collaborative group called American and European NEtwork of Antisynthetase Syndrome (AENEAS) for the study of this rare and fascinating disease. The group collected and published one of the largest series of ASSD patients ever described and with one of the longer follow-up ever reported. The number of participating centers is steadily increasing, as well as the available cohort. In the first paper, we showed that arthritis, myositis, and ILD may be frequently the only feature at disease onset, raising problems to reach a correct diagnosis of this syndrome. Nevertheless, we first observed that the ex novo appearance of further manifestations is common during the follow-up, strengthening the importance of a correct diagnosis. In our cohort, the 24 % of the 243 patients up to now collected had isolated arthritis as a presenting feature. These patients represent the most intriguing group in terms of differential diagnosis and clinical time course. Furthermore, data on this aspect are scanty, the reason that lead us to evaluate these aspects in our cohort of patients, reviewing also available literature. In fact, the most relevant aspect is that ASSD is rarely suspected in this setting of patients, in particular in case of poliarticular involvement, positive rheumatoid factor (RF), or anti-cyclic citrullinated peptide antibodies (ACPA) or evidence of joint erosions at plain radiographs. These findings were not rare in our cohort, and they have been also described in other series. Furthermore, manifestations such as Raynaud’s phenomenon, mechanic’s hands, and fever that may lead to the suspect of ASSD are observed only in a third of cases. If we consider the high rate of clinical picture progression in these patients, we fee

Published
2017

21. Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study

Author

Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Giraldo W. A. S., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Murcia T. P., La Corte R., Furini F., Foschi V., Corral J. B., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Montecucco C., Gonzalez-Gay M. A., Rosenthal K., Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Murcia, T, La Corte, R, Furini, F, Foschi, V, Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Montecucco, C, Gonzalez-Gay, M, Rosenthal, K, AENEAS (American, European NEtwork of Antisynthetase Syndrome) collaborative group, [Cavagna,L, Caporali,L, Montecucco,C] Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foudation, Pavia, Italy. [Nuño,L] Servicio de Reumatología, Hospital Universitario La Paz, Madrid, Spain. [Scire,CA] Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy. [Govoni ,M, Furini,F, La Corte,R, Foschi,V] UOC Reumatologia, Azienda Ospedaliero Universitaria S. Anna, University of Ferrara, Ferrara, Italy. [Lopez Longo.FJ, Martínez-Barrio,J, Hinojosa,M] Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Franceschini,F, Airó,P, Cavazzana,I] Rheumatology Unit, University and AO Spedali Civili, Brescia, Italy. [Neri,R, Barsotti,S] Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. [Castañeda,S] Department of Rheumatology, Hospital Universitario de la Princesa, IIS Princesa, Madrid, Spain.[Sifuentes Giraldo,WA, Bachiller Corral,AJ] Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain. [Iannone,F] Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy. [Fusaro,E, Parisi,S] Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy. [Paolazzi,G, Barausse,G, Bortolotti,R] Rheumatology Unit, Santa Chiara Hospital, Trento, Italy. [Pellerito,R, Vitetta,R, Russo,A] Division of Rheumatology, Mauriziano Hospital, Turin, Italy. [Schwarting,A, Menke,J] Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany. [Saketkoo,LA] Tulane University Lung Center Tulane/UMC Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, USA. [Ortego-Centeno,N] Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain. [Quartuccio,L] Santa Maria della Misericordia Hospital, Udine, Italy. [Bartoloni,E] Clinic of Rheumatology, Department of Medical and Biological Sciences. Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy. [Specker,C] Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany. [Pina Murcia,T, and González-Gay,MA] Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain. [Triantafyllias,K] ACURA Rheumatology Center, Bad Kreuznach, Germany. [Bajocchi,G] Rheumatology Unit, Department of Internal Medicine, S. Maria Hospital—IRCCS, Reggio Emilia, Italy. [Bravi,E] Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy. [Selmi,C] Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Milano, Italy.

Subjects
Male, Pathology, Neurology, Anti Jo-1, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studies [Medical Subject Headings], Medizin, Arthritis, Antisynthetase syndrome, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Antinuclear, Masculino, Myositis, Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Medicine (all), Interstitial lung disease, Femenino, General Medicine, Middle Aged, Diseases::Musculoskeletal Diseases::Muscular Diseases::Myositis [Medical Subject Headings], Humanos, Anticuerpos antinucleares, Antibodies, Antinuclear, Diseases::Musculoskeletal Diseases::Joint Diseases::Arthritis [Medical Subject Headings], Female, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Autoantibodies::Antibodies, Antinuclear [Medical Subject Headings], Adult, medicine.medical_specialty, Check Tags::Male [Medical Subject Headings], Antibodies, NO, Estudios retrospectivos, Internal medicine, medicine, Humans, Risk factor, Aged, Retrospective Studies, Persons::Persons::Age Groups::Adult [Medical Subject Headings], Artritis, business.industry, Retrospective cohort study, Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Anti Jo-1, Antisynthetase Syndrome, medicine.disease, Dermatology, Rheumatology, Check Tags::Female [Medical Subject Headings], Miositis, antisynthetase syndrome, business
Abstract

Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). These manifestations usually co-occur (for practical purpose complete forms) in the same patient, but cases with only 1 or 2 of these findings (for practical purpose incomplete forms) have been described. In incomplete forms, the ex novo occurrence of further manifestations is possible, although with frequencies and timing not still defined. The aim of this international, multicenter, retrospective study was to characterize the clinical time course of anti Jo-1 positive ASSD in a large cohort of patients. Included patients should be anti Jo-1 positive and with at least 1 feature between arthritis, myositis, and ILD. We evaluated the differences between complete and incomplete forms, timing of clinical picture appearance and analyzed factors predicting the appearance of further manifestations in incomplete ASSD. Finally, we collected 225 patients (58 males and 167 females) with a median follow-up of 80 months. At the onset, complete ASSD were 44 and incomplete 181. Patients with incomplete ASSD had frequently only 1 of the classic triad findings (110 cases), in particular, isolated arthritis in 54 cases, isolated myositis in 28 cases, and isolated ILD in 28 cases. At the end of follow-up, complete ASSD were 113, incomplete 112. Only 5 patients had an isolated arthritis, only 5 an isolated myositis, and 15 an isolated ILD. During the follow-up, 108 patients with incomplete forms developed further manifestations. Single main feature onset was the main risk factor for the ex novo appearance of further manifestation. ILD was the prevalent ex novo manifestation (74 cases). In conclusion, ASSD is a condition that should be carefully considered in all patients presenting with arthritis, myositis, and ILD, even when isolated. The ex novo appearance of further manifestations in patients with incomplete forms is common, thus indicating the need for an adequate clinical and instrumental follow-up. Furthermore, the study clearly suggested that in ASSD multidisciplinary approach involving Rheumatology, Neurology, Pneumology, and Internal Medicine specialists is mandatory. CA extern

Published
2015

22. Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement

Author

Marchesoni, A., D Angelo, S., Anzidei, M., Bortolotti, R., Cantini, F., Caramella, D., Carotti, M., Maria Sole Chimenti, Delle Sedie, A., Egan, C. G., Fabbroni, M., Frediani, B., Fusaro, E., Galeazzi, M., Gallazzi, M. B., Gentileschi, S., Gentili, F., Gerli, R., Gilio, M., Iannone, F., La Paglia, E., Lubrano, E., Macarini, L., Olivieri, I., Pellerito, R., Ramonda, R., Salvarani, C., Scarano, E., Scarpa, R., Spaggiari, L., Spanò, A., Zawaideh, J. P., Mazzei, M. A., Marchesoni, Antonio, D'Angelo, Salvatore, Anzidei, Michele, Bortolotti, Roberto, Cantini, Fabrizio, Caramella, Davide, Carotti, Marina, Chimenti, Maria Sole, Delle Sedie, Andrea, Egan, Colin Gerard, Fabbroni, Marta, Frediani, Bruno, Fusaro, Enrico, Galeazzi, Mauro, Gallazzi, Mauro Battista, Gentileschi, Stefano, Gentili, Francesco, Gerli, Roberto, Gilio, Michele, Iannone, Florenzo, La Paglia, Ernesto, Lubrano, Ennio, Macarini, Luca, Olivieri, Ignazio, Pellerito, Raffaele, Ramonda, Roberta, Salvarani, Carlo, Scarano, Enrico, Scarpa, Raffaele, Spaggiari, Lucia, Spanò, Angelo, Zawaideh, Jeries Paolo, and Mazzei, Maria Antonietta

Subjects
Consensus, Delphi Technique, Consensu, Humans, Interdisciplinary Communication, Italy, Radiologists, Rheumatologists, Spondylarthritis, Settore MED/16 - Reumatologia, Radiologist, Rheumatologist, Human
Abstract

The aim of this study was to develop a Delphi consensus statement between rheumatologists and radiologists for the diagnosis and monitoring of axial spondyloarthritis (axial-SpA).Following an extensive literature search to identify unmet needs and potential goals for a multidisciplinary approach, a scientific board comprising 28 Italian hospital-based rheumatologists (n=19) and radiologists (n=9) identified 8 "starting points", resulting in the development of 23 consensus statements covering issues from current practice guidelines to specific MRI protocols for the assessment of axial-SpA. Each participant anonymously expressed a level of agreement for each statement using a 5-point Likert scale (1="strongly disagree"; 5="strongly agree") via an online Delphi method.Total cumulative agreement (TCA) was defined as the sum of the percentage of response to items 4 ("agree") and 5 ("absolutely agree"). Consensus was defined as ≥80% total cumulative agreement for each statement.After the first round of voting (28 participants), positive consensus was reached for 28/31 (90.3%) statements. Statements without consensus (n=3) were discussed in a face-to-face plenary session prior to the second vote (28 participants). After the second round voting, positive consensus was attained for all 31 statements, with mean final TCA of 95.5% (range 82.1-100%).This Delphi consensus statement provides an aid to rheumatologists and radiologists for the diagnosis and monitoring of axial-SpA.

Published
2018

23. Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study

Author

Palareti, G, Legnani, C, Cosmi, B, Antonucci, E, Erba, N, Poli, D, Testa, S, Tosetto, A, De Micheli, V, Ghirarduzzi, A, Veropalumbo, MR, Chiara, UM, Prisco, D, Aterotrombotiche, M, Paoletti O, Falanga, A, Luigi, S, Donadini, M, Rancan, E, Quintavalla, R, Ferrini, PM, Santoro, RC, Orlandini, F, Benedetti, R, Cattaneo, M, Lussana, F, Bertinato, E, Cappelli, R, Pizzini, AM, Angeloni, L, D'angelo, A, Crippa, L, Bortolotti, R, Vandelli, MR, Palareti, G, Legnani, C, Cosmi, B, Antonucci, E, Erba, N, Poli, D, Testa, S, Tosetto, A, De Micheli, V, Ghirarduzzi, A, Veropalumbo, M, Chiara, U, Prisco, D, Aterotrombotiche, M, Paoletti, O, Falanga, A, Luigi, S, Donadini, M, Rancan, E, Quintavalla, R, Ferrini, P, Santoro, R, Orlandini, F, Benedetti, R, Cattaneo, M, Lussana, F, Bertinato, E, Cappelli, R, Pizzini, A, Angeloni, L, D'Angelo, A, Crippa, L, Bortolotti, R, Vandelli, M, G. PALARETI, C. LEGNANI, B. COSMI, E. ANTONUCCI, N. ERBA, D. POLI, S. TESTA, A. TOSETTO, and ON BEHALF OF THE DULCIS (D-DIMER-ULTRASONOGRAPHY IN COMBINATION ITALIAN STUDY) INVESTIGATORS

Subjects
0301 basic medicine, Male, Cutoff criteria, medicine.medical_specialty, recurrence, Clinical Biochemistry, venous thromboembolism, Individual risk, Clinical biochemistry, Fibrin Fibrinogen Degradation Products, 03 medical and health sciences, Reference Values, Risk Factors, Internal medicine, D-dimer, medicine, Cutoff, Humans, Aged, Aged, 80 and over, business.industry, Biochemistry (medical), Anticoagulants, Hematology, General Medicine, Middle Aged, Surgery, Recurrent event, 030104 developmental biology, Reference values, Female, business, Venous thromboembolism
Abstract

SummaryIntroduction D-dimer assay, generally evaluated according to cutoff points calibrated for VTE exclusion, is used to estimate the individual risk of recurrence after a first idiopathic event of venous thromboembolism (VTE). Methods Commercial D-dimer assays, evaluated according to predetermined cutoff levels for each assay, specific for age (lower in subjects

Published
2016

24. Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: Results from an international retrospective multicenter study

Author

Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Murcia, T, La Corte, R, Furini, F, Foschi, V, Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Montecucco, C, Gonzalez-Gay, M, Rosenthal, K, Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Giraldo W. A. S., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Murcia T. P., La Corte R., Furini F., Foschi V., Corral J. B., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Montecucco C., Gonzalez-Gay M. A., Rosenthal K., Cavagna, L, Nuno, L, Scire, C, Govoni, M, Longo, F, Franceschini, F, Neri, R, Castaneda, S, Giraldo, W, Caporali, R, Iannone, F, Fusaro, E, Paolazzi, G, Pellerito, R, Schwarting, A, Saketkoo, L, Ortego-Centeno, N, Quartuccio, L, Bartoloni, E, Specker, C, Murcia, T, La Corte, R, Furini, F, Foschi, V, Corral, J, Airo, P, Cavazzana, I, Martinez-Barrio, J, Hinojosa, M, Giannini, M, Barsotti, S, Menke, J, Triantafyllias, K, Vitetta, R, Russo, A, Bajocchi, G, Bravi, E, Barausse, G, Bortolotti, R, Selmi, C, Parisi, S, Montecucco, C, Gonzalez-Gay, M, Rosenthal, K, Cavagna L., Nuno L., Scire C. A., Govoni M., Longo F. J. L., Franceschini F., Neri R., Castaneda S., Giraldo W. A. S., Caporali R., Iannone F., Fusaro E., Paolazzi G., Pellerito R., Schwarting A., Saketkoo L. A., Ortego-Centeno N., Quartuccio L., Bartoloni E., Specker C., Murcia T. P., La Corte R., Furini F., Foschi V., Corral J. B., Airo P., Cavazzana I., Martinez-Barrio J., Hinojosa M., Giannini M., Barsotti S., Menke J., Triantafyllias K., Vitetta R., Russo A., Bajocchi G., Bravi E., Barausse G., Bortolotti R., Selmi C., Parisi S., Montecucco C., Gonzalez-Gay M. A., and Rosenthal K.

Abstract

Anti Jo-1 antibodies are the main markers of the anti-synthetase syndrome (ASSD), an autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial lung disease (ILD). These manifestations usually co-occur (for practical purpose complete forms) in the same patient, but cases with only 1 or 2 of these findings (for practical purpose incomplete forms) have been described. In incomplete forms, the ex novo occurrence of further manifestations is possible, although with frequencies and timing not still defined. The aim of this international, multicenter, retrospective study was to characterize the clinical time course of anti Jo-1 positive ASSD in a large cohort of patients. Included patients should be anti Jo-1 positive and with at least 1 feature between arthritis, myositis, and ILD. We evaluated the differences between complete and incomplete forms, timing of clinical picture appearance and analyzed factors predicting the appearance of further manifestations in incomplete ASSD. Finally, we collected 225 patients (58 males and 167 females) with a median follow-up of 80 months. At the onset, complete ASSD were 44 and incomplete 181. Patients with incomplete ASSD had frequently only 1 of the classic triad findings (110 cases), in particular, isolated arthritis in 54 cases, isolated myositis in 28 cases, and isolated ILD in 28 cases. At the end of follow-up, complete ASSD were 113, incomplete 112. Only 5 patients had an isolated arthritis, only 5 an isolated myositis, and 15 an isolated ILD. During the follow-up, 108 patients with incomplete forms developed further manifestations. Single main feature onset was the main risk factor for the ex novo appearance of further manifestation. ILD was the prevalent ex novo manifestation (74 cases). In conclusion, ASSD is a condition that should be carefully considered in all patients presenting with arthritis, myositis, and ILD, even when isolated. The ex novo appearance of further manifestati

Published
2015

25. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study

Author

Palareti, G, Cosmi, B, Legnani, C, Antonucci, E, De Micheli, V, Ghirarduzzi, A, Poli, D, Testa, S, Tosetto, A, Pengo, V, Prandoni, P, Erba, N, Veropalumbo, M, Chiara, U, Prisco, D, Paoletti, O, Falanga, A, Luigi, S, Donadini, M, Rancan, E, Quintavalla, R, Ferrini, P, Santoro, R, Orlandini, F, Benedetti, R, Cattaneo, M, Lussana, F, Bertinato, E, Cappelli, R, Pizzini, A, Angeloni, L, D'Angelo, A, Crippa, L, Bortolotti, R, Vandelli, M, Ageno, W, Tripodi, A, Imberti, D, Moia, M, Pesavento, R, Magrini, N, Marongiu, F, Zonzin, P, Piaggesi, N, Silingardi, M, Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P, Erba N, Veropalumbo MR, Chiara UM, Prisco D, Paoletti O, Falanga A, Luigi S, Donadini M, Rancan E, Quintavalla R, Ferrini PM, Santoro RC, Orlandini F, Benedetti R, Cattaneo M, Lussana F, Bertinato E, Cappelli R, Pizzini AM, Angeloni L, D'Angelo A, Crippa L, Bortolotti R, Vandelli MR, Ageno W, Tripodi A, Imberti D, Moia M, Pesavento R, Magrini N, Marongiu F, Zonzin P, Piaggesi N, Silingardi M, Palareti, G, Cosmi, B, Legnani, C, Antonucci, E, De Micheli, V, Ghirarduzzi, A, Poli, D, Testa, S, Tosetto, A, Pengo, V, Prandoni, P, Erba, N, Veropalumbo, M, Chiara, U, Prisco, D, Paoletti, O, Falanga, A, Luigi, S, Donadini, M, Rancan, E, Quintavalla, R, Ferrini, P, Santoro, R, Orlandini, F, Benedetti, R, Cattaneo, M, Lussana, F, Bertinato, E, Cappelli, R, Pizzini, A, Angeloni, L, D'Angelo, A, Crippa, L, Bortolotti, R, Vandelli, M, Ageno, W, Tripodi, A, Imberti, D, Moia, M, Pesavento, R, Magrini, N, Marongiu, F, Zonzin, P, Piaggesi, N, Silingardi, M, Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P, Erba N, Veropalumbo MR, Chiara UM, Prisco D, Paoletti O, Falanga A, Luigi S, Donadini M, Rancan E, Quintavalla R, Ferrini PM, Santoro RC, Orlandini F, Benedetti R, Cattaneo M, Lussana F, Bertinato E, Cappelli R, Pizzini AM, Angeloni L, D'Angelo A, Crippa L, Bortolotti R, Vandelli MR, Ageno W, Tripodi A, Imberti D, Moia M, Pesavento R, Magrini N, Marongiu F, Zonzin P, Piaggesi N, and Silingardi M

Abstract

The optimal duration of anticoagulation in patients with venous thromboembolism (VTE) is uncertain. We investigated whether persistently negative D-dimers in patients with vein recanalization or stable thrombotic burden can identify subjects at low recurrence risk. Outpatients with a first VTE (unprovoked or associated with weak risk factors) were eligible after at least 3 months (12 in those with residual thrombosis) of anticoagulation. They received serial D-dimer measurements using commercial assays with predefined age/sex-specific cutoffs and were followed for up to 2 years. Of 1010 patients, anticoagulation was stopped in 528 (52.3%) with persistently negative D-dimer who subsequently experienced 25 recurrences (3.0% pt-y; 95% confidence interval [CI], 2.0-4.4%). Of the remaining 482 patients, 373 resumed anticoagulation and 109 refused it. Recurrent VTE developed in 15 patients (8.8% pt-y; 95% CI, 5.0-14.1) of the latter group and in 4 of the former (0.7% pt-y; 95% CI, 0.2-1.7; hazard ratio 5 2.92; 95% CI, 1.87-9.72; P 5 .0006). Major bleeding occurred in 14 patients (2.3% pt-y;95%CI, 1.3-3.9)whoresumedanticoagulation. Serial D-dimer measurement is suitable in clinical practice for the identification of VTE patients in whom anticoagulation can be safely discontinued. This study was registered at clinicaltrials.gov as #NCT00954395

Published
2014

26. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study

Author

Palareti G, Cosmi B, Legnani C, Antonucci E, De Micheli V, Ghirarduzzi A, Poli D, Testa S, Tosetto A, Pengo V, Prandoni P, Erba N, Veropalumbo MR, Chiara UM, Prisco D, Paoletti O, Falanga A, Luigi S, Donadini M, Rancan E, Quintavalla R, Ferrini PM, Santoro RC, Orlandini F, Benedetti R, Cattaneo M, Lussana F, Bertinato E, Cappelli R, Pizzini AM, Angeloni L, D'Angelo A, Crippa L, Bortolotti R, Vandelli MR, Ageno W, Tripodi A, Imberti D, Moia M, Pesavento R, Magrini N, Marongiu F, Zonzin P, Piaggesi N, Silingardi M, Palareti, G, Cosmi, B, Legnani, C, Antonucci, E, De Micheli, V, Ghirarduzzi, A, Poli, D, Testa, S, Tosetto, A, Pengo, V, Prandoni, P, Erba, N, Veropalumbo, M, Chiara, U, Prisco, D, Paoletti, O, Falanga, A, Luigi, S, Donadini, M, Rancan, E, Quintavalla, R, Ferrini, P, Santoro, R, Orlandini, F, Benedetti, R, Cattaneo, M, Lussana, F, Bertinato, E, Cappelli, R, Pizzini, A, Angeloni, L, D'Angelo, A, Crippa, L, Bortolotti, R, Vandelli, M, Ageno, W, Tripodi, A, Imberti, D, Moia, M, Pesavento, R, Magrini, N, Marongiu, F, Zonzin, P, Piaggesi, N, Silingardi, M, Gualtiero Palareti, Benilde Cosmi, Cristina Legnani, Emilia Antonucci, Valeria De Micheli, Angelo Ghirarduzzi, Daniela Poli, Sophie Testa, Alberto Tosetto, Vittorio Pengo, and and Paolo Prandoni, on behalf of the DULCIS (D-dimer and ULtrasonography in Combination Italian Study) Investigators

Subjects
Male, medicine.medical_specialty, Time Factors, Immunology, Biochemistry, Drug Administration Schedule, Fibrin Fibrinogen Degradation Products, Pregnancy, Recurrence, Internal medicine, D-dimer, medicine, Humans, D-dimer, venous thromboembolism, vitamin K antagonists, Vein, Aged, Hematology, business.industry, Hazard ratio, Anticoagulants, Cell Biology, Venous Thromboembolism, Middle Aged, medicine.disease, Thrombosis, Confidence interval, Surgery, Clinical trial, medicine.anatomical_structure, Treatment Outcome, Withholding Treatment, Female, business, anticoagulation, fibrin fragment d substance, venous thromboembolism, recurrence risk, Follow-Up Studies
Abstract

The optimal duration of anticoagulation in patients with venous thromboembolism (VTE) is uncertain. We investigated whether persistently negative D-dimers in patients with vein recanalization or stable thrombotic burden can identify subjects at low recurrence risk. Outpatients with a first VTE (unprovoked or associated with weak risk factors) were eligible after at least 3 months (12 in those with residual thrombosis) of anticoagulation. They received serial D-dimer measurements using commercial assays with predefined age/sex-specific cutoffs and were followed for up to 2 years. Of 1010 patients, anticoagulation was stopped in 528 (52.3%) with persistently negative D-dimer who subsequently experienced 25 recurrences (3.0% pt-y; 95% confidence interval [CI], 2.0-4.4%). Of the remaining 482 patients, 373 resumed anticoagulation and 109 refused it. Recurrent VTE developed in 15 patients (8.8% pt-y; 95% CI, 5.0-14.1) of the latter group and in 4 of the former (0.7% pt-y; 95% CI, 0.2-1.7; hazard ratio = 2.92; 95% CI, 1.87-9.72; P = .0006). Major bleeding occurred in 14 patients (2.3% pt-y; 95% CI, 1.3-3.9) who resumed anticoagulation. Serial D-dimer measurement is suitable in clinical practice for the identification of VTE patients in whom anticoagulation can be safely discontinued. This study was registered at clinicaltrials.gov as #NCT00954395.

Published
2014

30. The 158VV Fcgamma Receptor IIIA genotype predicts a positive response to Rituximab in Rheumatoid Arthritis: analysis in a large cohort of italian patients

Author

Fabris, M., Quartuccio, L., Pontarini, E., Zabotti, A., Benucci, M., Manfredi, M., Biasi, Domenico, Ravagnani, Viviana, Atzeni, F., Morassi, P., Fischetti, F., Bazzicchi, L., Saracco, M., Pellerito, R., Cimmino, M., Carraro, V., Semeraro, A., Caporali, R., Cavagna, L., Bortolotti, R., Govoni, M., Bombardieri, S., and De Vita, S.

Subjects
Rheumatoid Arthritis, predictors, Outcome assessment
Published
2012

31. The TTTT BLyS promoter haplotype associates with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to TNF blockers

Author

Fabris, M, Quartuccio, L, Vital, E, Pontarini, E, Salvin, S, Fabro, C, Zabotti, A, Benucci, M, Manfredi, M, Ravagnani, V, Biasi, D, Atzeni, F, Sarzi Puttini, P, Morassi, P, Fischetti, F, Bazzicchi, L, Saracco, M, Pellerito, R, Cimmino, M, Carraro, V, Semeraro, A, Schiavon, F, Caporali, R, Bortolotti, R, Govoni, Marcello, Fogolari, F, Tonutti, E, Bombardieri, S, Emery, P, De Vita, S., M., Fabri, L., Quartuccio, E., Vital, E., Pontarini, S., Salvin, C., Fabro, A., Zabotti, M., Benucci, M., Manfredi, V., Ravagnani, D., Biasi, F., Atzeni, P., Sarzi Puttini, P., Morassi, Fischetti, Fabio, L., Bazzicchi, M., Saracco, R., Pellerito, M., Cimmino, V., Carraro, A., Semeraro, F., Schiavon, R., Caporali, R., Bortolotti, M., Govoni, F., Fogolari, E., Tonutti, S., Bombardieri, P., Emery, and S. D., Vita

Subjects
rheumatoid arthritis, "B lymphocyte, BLyS, rituximab, polymorphism, synovitis", therapeutic response, biologic therapy, TTTT BLys promoter, rheumatoid arthriti
Abstract

OBJECTIVE.: To investigate the polymorphisms in the promoter region of B-Lymphocyte Stimulator (BLyS) gene as markers of response to rituximab (RTX) in rheumatoid arthritis (RA). METHODS.: The study was first conducted in 152 Italian RA patients and then replicated in 117 patients (73 Italian, 44 British). Response to therapy (DAS28; EULAR criteria) was evaluated at months +4 and +6 after RTX and patients were classified according to the best response they showed during this period. BLyS promoter polymorphisms were analyzed by RFLP-PCR, BLyS promoter haplotypes by Expectation-Maximization algorithm and BLyS serum levels by ELISA. RESULTS.: The TTTT BLyS promoter haplotype appeared significantly associated with response to RTX only in the subset of seropositive (rheumatoid factor and/or anti-CCP positive) patients. The replication series confirmed that this association was limited to seropositive RA patients who previously failed anti-tumor necrosis factor (TNF) agents. In the whole series of anti-TNF-failure seropositive patients, TTTT-carrying patients were more prevalent in good responders (18/43; 41.9\%) than in moderate (20/83; 24.1\%) and in non responders (1/21; 4.8\%), (good vs. non responders: OR 14.4, 95\%CI:1.77-117.39, p=0.0028). Furthermore, the TTTT BLyS haplotype was selected as an independent marker of good response to RTX by multivariate analysis (good vs. non responders: OR 16.2, 95\% CI 1.7-152.5; p=0.01; good vs. moderate plus non responders: OR 3.05, 95\%CI:1.19-7.82, p=0.02). The relationship between BLyS polymorphims and BLyS serum levels remained unclear. CONCLUSION.: BLyS promoter genotyping may be suitable to identify seropositive RA patients who may show good response to RTX after anti-TNF agents failure.

Published
2012

33. AB0371 Clinical Significance of Anti-Adalimumab Antibodies in Rheumatoid Arthritis, Ankylosing Spondilitis and Psoriasic Arthritis

Author

Hoxha, A., primary, Calligaro, A., additional, Tonello, M., additional, Carletto, A., additional, Paolazzi, G., additional, Bortolotti, R., additional, Felicetti, M., additional, Ramonda, R., additional, Del Ross, T., additional, Grava, C., additional, Boaretto, M., additional, Favaro, M., additional, Teghil, V., additional, Ruffatti, A., additional, and Punzi, L., additional

Published
2014
Full Text
View/download PDF

34. FRI0053 Comparison of the Risk of Developing Comorbities and Adverse Events by Type of Diagnosis: Results from the Lorhen Registry

Author

Atzeni, F., primary, Ricci, C., additional, Caporali, R., additional, Marchesoni, A., additional, Bongiovanni, S., additional, Favalli, E., additional, Gorla, R., additional, Pellerito, R., additional, Filippini, M., additional, Todoerti, M., additional, Paolazzi, G., additional, Bortolotti, R., additional, Fusaro, E., additional, and Sarzi-Puttini, P., additional

Published
2014
Full Text
View/download PDF

38. AB0311 The 158vv fcgamma receptor iiia genotype predicts a positive response to rituximab in rheumatoid arthritis: Analysis in a large cohort of italian patients

Author

Fabris, M., primary, Quartuccio, L., additional, Pontarini, E., additional, Zabotti, A., additional, Benucci, M., additional, Manfredi, M., additional, Biasi, D., additional, Ravagnani, V., additional, Atzeni, F., additional, Morassi, P., additional, Fischetti, F., additional, Bazzicchi, L., additional, Saracco, M., additional, Pellerito, R., additional, Cimmino, M., additional, Carraro, V., additional, Semeraro, A., additional, Caporali, R., additional, Cavagna, L., additional, Bortolotti, R., additional, Govoni, M., additional, Bombardieri, S., additional, and De Vita, S., additional

Published
2013
Full Text
View/download PDF

39. FRI0255 The 158vv fcgamma receptor 3a genotype is associated with response to rituximab in rheumatoid arthritis: results of an italian multicentre study

Author

Quartuccio, L., primary, Fabris, M., additional, Pontarini, E., additional, Salvin, S., additional, Zabotti, A., additional, Benucci, M., additional, Manfredi, M., additional, Biasi, D., additional, Ravagnani, V., additional, Atzeni, F., additional, Sarzi Puttini, P., additional, Morassi, P., additional, Fischetti, F., additional, Tomietto, P., additional, Bazzichi, L., additional, Saracco, M., additional, Pellerito, R., additional, Cimmino, M., additional, Schiavon, F., additional, Carraro, V., additional, Semeraro, A., additional, Caporali, R., additional, Cavagna, L., additional, Bortolotti, R., additional, Paolazzi, G., additional, Govoni, M., additional, Bombardieri, S., additional, and De Vita, S., additional

Published
2013
Full Text
View/download PDF

42. Does atopy last forever?

Author

Zauli, D., primary, Bortolotti, R., additional, Grassi, A., additional, Ballardini, G., additional, D'Ecclesia, A., additional, and Bianchi, F.B., additional

Published
2005
Full Text
View/download PDF

44. Anti-.

Author

Granito, A., Zauli, D., Muratori, P., Muratori, L., Grassi, A., Bortolotti, R., Petrolini, N., Veronesi, L., Gionchetti, P., Bianchi, F. B., and Volta, U.

Subjects
IMMUNOGLOBULINS, CELIAC disease, AUTOIMMUNITY, DIARRHEA, INFLAMMATORY bowel diseases, ULCERATIVE colitis
Abstract

: Anti-Saccharomyces cerevisiaeand perinuclear anti-neutrophil cytoplasmic autoantibodies are markers of Crohn's disease and ulcerative colitis respectively.: To determine the prevalence of anti-S. cerevisiaeand perinuclear anti-neutrophil cytoplasmic autoantibodies in a large series of coeliac disease patients before and after gluten free diet, and to correlate anti-S. cerevisiae-positivity with intestinal mucosal damage.: One hundred and five consecutive coeliac disease patients and 141 controls (22 ulcerative colitis, 24 Crohn's disease, 30 primary sclerosing cholangitis, 15 postenteritis syndrome, 50 blood donors) were tested for anti-S. cerevisiaeby enzyme-linked immunosorbent assay and for perinuclear anti-neutrophil cytoplasmic autoantibodies by indirect immunofluorescence.: In coeliac disease anti-S. cerevisiae(immunoglobulin G and/or immunoglobulin A) were slightly less frequent (59%) than in Crohn's disease (75%,P = 0.16) and significantly more frequent than in ulcerative colitis (27%), primary sclerosing cholangitis (30%), postenteritis syndrome (26%) and blood donors (4%) (P = 0.009,P = 0.0002,P = 0.025,P < 0.0001). No correlation was found between anti-S. cerevisiaeand degree of mucosal damage. Perinuclear anti-neutrophil cytoplasmic autoantibodies were detected only in one coeliac. After gluten free diet the disappearance of anti-S. cerevisiae-immunoglobulin A (93%) was more frequent than that of immunoglobulin G (17%,P = 0.0001); perinuclear anti-neutrophil cytoplasmic autoantibodies disappeared in the only coeliac positive at diagnosis.: More than half of untreated coeliacs are anti-S. cerevisiae-positive irrespective of the severity of mucosal damage. Differently from immunoglobulin A, anti-S. cerevisiae-immunoglobulin G persisted in more than 80% after gluten free diet. The high prevalence of anti-S. cerevisiaein coeliac disease suggests that they may be the effect of a non-specific immune response in course of chronic small bowel disease. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results